For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Study of Brain Network Activation Technology in Treating Depression

Clinical Trial Title: 
The relationship among changes in brain activity and changes in symptoms of depression in adults with major depressive disorder treated with an FDA-approved antidepressant.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
John Zajecka, MD
Clinical Trial Protocol Description: 

This is a study to evaluate whether brain network activation technology can predict the effects of treatment for depression with an FDA-approved antidepressant.

Recent studies have shown that brain network activation analysis (BNA) may be used as a tool to improve diagnosis and monitor treatment response in major depressive disorder. BNA is a method of analyzing brain activity using a series of EEG (electroencephalogram) recording sessions. During the EEG, your brain waves are recorded as you perform a series of tasks on a computer screen. The EEG procedure will last approximately 1½ to 2 hours and is performed 4 times during the study.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are 18 to 65 years of age.
  • Have been diagnosed with depression.
  • Are right-handed.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a primary psychiatric disorder other than depression.
  • Have a condition that may interfere with the EEG recording (such as a hair or scalp condition, severe head injury, Alzheimer’s or Parkinson’s disease, etc.).
  • Are pregnant or breastfeeding, or have an unstable medical condition.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Mental Health Disorders
Contact Phone: 
(312) 942-6597
Contact Name: 
Linda Skaggs